Erin Sullivan, OD
Optometrist · Saint Louis, MONPI 1205825080
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 302 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Among optometrist clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 302 payments — averaging $21.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Sun Pharmaceutical Industries Inc.$614
- Novartis$601
- Alcon$588
- Johnson & Johnson Surgical Vision, Inc.$376
- Bausch & Lomb Americas Inc.$366
- plus $3K from 25 others
Across 38 payments — averaging $2945.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$112K
What the payments were for
- Food & beverage$6,45299%
- Education$180%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 60 | $1,169 |
| Sun Pharmaceutical Industries Inc. | 25 | $614 |
| Novartis | 30 | $601 |
| Alcon | 28 | $588 |
| Johnson & Johnson Surgical Vision, Inc. | 18 | $376 |
| Bausch & Lomb Americas Inc. | 20 | $366 |
| Kala Pharmaceuticals, Inc. | 14 | $364 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $301 |
| Oyster Point Pharma, Inc. | 13 | $283 |
| Tarsus Pharmaceuticals, Inc. | 10 | $278 |
| Dompe US, Inc. | 7 | $258 |
| Harrow Eye, LLC | 10 | $198 |
| Eyevance Pharmaceuticals LLC | 9 | $144 |
| Amgen(2 entities) | 6 | $142 |
| Johnson & Johnson Vision Care, Inc. | 4 | $139 |
| Sight Sciences, Inc. | 12 | $136 |
| Glaukos Corporation | 4 | $113 |
| Aerie Pharmaceuticals, Inc. | 4 | $71 |
| ANI Pharmaceuticals, Inc. | 2 | $50 |
| The Cameron-ehlen Group, Inc. | 1 | $49 |
| Mallinckrodt Hospital Products Inc. | 1 | $36 |
| Shire North American Group Inc | 2 | $30 |
| LKC Technologies, Inc. | 1 | $29 |
| Alcon Research LLC | 2 | $25 |
| Merz Pharmaceuticals, LLC | 2 | $24 |
| Santen Inc. | 1 | $24 |
| Coopervision Inc. | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Tearlab Corp | 1 | $18 |
| Rxsight Inc | 1 | $16 |
| Biotissue Holdings Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,489 in reported general payments places this provider in the 90th percentile of 1,030 optometrist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 83 | $97,712 |
| XiidraLifitegrast | 43 | $55,622 |
| Cyclosporine | 54 | $40,678 |
| MieboPerfluorohexyloctane/Pf | 21 | $20,419 |
| LumiganBimatoprost | 29 | $19,235 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 15 | $1,261 |
| Latanoprost | 116 | $1,208 |
| Prednisolone Acetate | 19 | $676 |
| Doxycycline Hyclate | 14 | $430 |
| Timolol Maleate | 16 | $179 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 14 | $160 |
| ErythromycinErythromycin Base | 15 | $119 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 11 | $91 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $1,169 | $116,947112 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $366 | $76,04164 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,030 optometrist providers in Missouri.
Other optometrist in Saint Louis
- John McGrealSaint Louis$126K
- Ariel CerenzieSaint Louis$76K
- Paul LuongSaint Louis$44K
- Robert EnsleySaint Louis$38K
- Andrew RoyerSaint Louis$23K
- Robert BrusattiSaint Louis$20K
- Edward BennettSaint Louis$13K
- Craig SorceSaint Louis$8K
- Julie DekinderSaint Louis$8K
- Kathryn NoonanSaint Louis$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.